Myriad Genetics Inc reported results for the 2026 quarter with revenue of $190.7M, a net loss of ($43.2M) and diluted loss per share of ($0.46), reflecting lower revenue and improved loss versus the prior-year quarter.
Financial Highlights
| MetricCurrent quarterPrior year quarterYoY change | Revenue¹$190.7M$213.1M(10.5%) | Net income²($43.2M)($330.5M)86.9% | Diluted EPS³($0.46)($3.57)87.1% |
¹ Reported as “Revenue”. ² Reported as “Net loss”. ³ Reported as “Diluted loss per share”.
Business Highlights
- Revenue trends: Total revenue declined year‑over‑year (YTD roughly $391.1M vs $409.0M) driven by lower reimbursement and estimate adjustments.
- Channel and volume mix: Cancer volumes increased about 9% YTD while Prenatal volumes fell roughly 11%; Mental Health volumes grew about 5%.
- Pricing and reimbursement: Revenue per test declined across Cancer Care and Prenatal segments due to reimbursement reductions.
- Commercial investment: Increased sales and marketing spend to expand commercial reach; launched Prolaris + AI and expanded Precise MRD offerings.
- Operational focus: Engaged professional services to boost efficiency, appointed a new CTO, and expanded clinical evidence to support scale.
Original SEC Filing:
This is an AI-powered summary. It may contain inaccuracies. Consider verifying important information with the source. Please note this summary is solely based on documents filed with the SEC.